[Federal Register Volume 65, Number 74 (Monday, April 17, 2000)]
[Notices]
[Page 20472]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-9446]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by contacting John Peter Kim, 
at the Office of Technology Transfer, National Institutes of Health, 
6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; 
telephone: 301/496-7056 ext. 264; fax: 301/402-0220; e-mail: 
[email protected]. A signed Confidential Disclosure Agreement will be 
required to receive copies of the patent applications.

High Speed Parallel Nucleic Acid Sequencing

Thomas D. Schneider, Denise Rubens (NCI)
Serial No. 60/151,580 filed 30 Aug 1999

    The present application describes a new method and apparatus for 
DNA sequencing called Two Dye Sequencing (TDS). This method employs 
engineered DNA polymerases which are labeled with a fluorophore such as 
Green Fluorescent Protein (GFP) and are combined with an annealed 
oligonucleotide primer in a chamber of a microscope field of view 
capable of detecting individual molecules. Four nucleotide 
triphosphates, each labeled on the base with a different fluorescent 
dye are introduced to the reaction. Light of a specific wavelength is 
used to excite the fluorophore on the polymerase, which in turn excites 
the neighboring fluorophore on the nucleotide by Fluorescense Resonance 
Energy Transfer (FRET). As nucleotides are added to the primer, their 
spectral emissions provide sequence information of the DNA molecule.

Hydrazide Inhibitors of HIV-1 Integrase

Yves Pommier, Nouri Neamati, Zhaiwai Lin, Terrence R. Burke, Jr. (NCI)
DHHS Reference Nos. E-037-99/0 filed 12 Mar 1999 and E-037-99/1 filed 
10 Mar 2000

    The human immunodeficiency virus (HIV) is the causative agent of 
acquired immunodeficiency syndrome (AIDS). Drug-resistance is a 
critical factor contributing to the gradual loss of clinical benefit to 
treatments for HIV infection. Accordingly, combination therapies have 
further evolved to address the mutating resistance of HIV. However, 
there has been great concern regarding the apparent growing resistance 
of HIV strains to current therapies.
    It has been found that a certain class of compounds including 
salicylhydrazides and analogs and derivatives thereof are effective and 
selective anti-integrase inhibitors which are active in the presence of 
both Mn(+2) and Mg(+2) and which may be used in the treatment or 
prevention of infection by HIV and AIDS. The subject invention provides 
for such compounds and for methods of inhibiting HIV integrase.

    Dated: April 5, 2000.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 00-9446 Filed 4-14-00; 8:45 am]
BILLING CODE 4140-01-P